DEBEL MARLENE
EVP & Chief Risk Officer
DEBEL MARLENE has filed 5 SEC Form 4 filings (9 transaction rows) across 2 companies, including MET, RJF, with disclosures dating back to 2026. 5 of those filings fall inside the rolling window. Most recent filing: Sep 2, 2026.
On the most recent filing, DEBEL MARLENE is listed as EVP & Chief Risk Officer at METLIFE INC. Inside the rolling window, DEBEL MARLENE reported no open-market purchases and 1 open-market sale totaling $1.7M in MET.
Companies traded
Other insiders at MET
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$1.7M
reported sales (SEC code S)
Companies
2
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has DEBEL MARLENE made?
DEBEL MARLENE has filed 5 SEC Form 4 filings (9 transaction rows) across 2 companies, including MET, RJF since 2026.
Which companies does DEBEL MARLENE trade?
DEBEL MARLENE has filed SEC Form 4 disclosures for 2 companies, including MET, RJF.
When was DEBEL MARLENE's most recent SEC Form 4 filing?
DEBEL MARLENE's most recent SEC Form 4 filing on Tracefour is dated Sep 2, 2026.
What is DEBEL MARLENE's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, DEBEL MARLENE is listed as EVP & Chief Risk Officer.
What is DEBEL MARLENE's total buy and sell value in the current window?
Inside the rolling retention window, DEBEL MARLENE bought $0 and sold $1.7M based on SEC Form 4 filings.
What was DEBEL MARLENE's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 21,312 MET shares on 2026-06-01, worth $1.7M, per SEC Form 4 filings.